World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
52904
World Ranking
7820
National Ranking
4076

Michael R. Grever publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael R. Grever sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 512 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael R. Grever D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael R. Grever sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 101 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2003 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Michael R. Grever is affiliated with The Ohio State University in the United States. Their research focuses primarily within the field of medicine, with significant contributions to genetics, pathology and forensic medicine, immunology, molecular biology, and oncology.

The scientist's work encompasses several key topics, including:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Acute Lymphoblastic Leukemia research
  • PI3K/AKT/mTOR signaling in cancer
  • Chronic Myeloid Leukemia Treatments
  • Advanced Breast Cancer Therapies

Frequent publication venues for Michael R. Grever include:

  • Blood
  • Leukemia
  • American Journal of Hematology
  • Journal of Clinical Oncology
  • Circulation

Notable recent papers authored or co-authored by Michael R. Grever are:

  • Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia, 2023, JACC CardioOncology
  • Ventricular arrhythmias and sudden death events following acalabrutinib initiation, 2022, Blood
  • Phase 2 study of ibrutinib in classic and variant hairy cell leukemia, 2021, Blood
  • The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib, 2021, Blood
  • Second cancer incidence in CLL patients receiving BTK inhibitors, 2020, Leukemia

Michael R. Grever has collaborated frequently with several researchers, including:

  • Kerry A. Rogers
  • Seema A. Bhat
  • Jennifer A. Woyach
  • Adam S. Kittai
  • James S. Blachly

Recognition in their professional field includes being named a Fellow of the American Association for the Advancement of Science (AAAS) in 2003 and membership in the Association of American Physicians.

Best Publications

  • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

    Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

    Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay

  • Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

    Andreas Rosenwald;Ash A. Alizadeh;George Widhopf;Richard Simon

  • The National Cancer Institute: cancer drug discovery and development program.

    Michael R. Grever;Saul A. Schepartz;Bruce A. Chabner

  • Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

    B D Cheson;P A Cassileth;D R Head;C A Schiffer

  • Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study

    Catherine P. Leith;Kenneth J. Kopecky;I-Ming Chen;Lisette Eijdems

  • Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

    Jeffrey G. Supko;Robert L. Hickman;Michael R. Grever;Louis Malspeis

  • Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

    Richard T. Kloos;Matthew D. Ringel;Michael V. Knopp;Nathan C. Hall

  • Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

    John C. Byrd;Timothy Murphy;Robin S. Howard;Margaret S. Lucas

  • Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

    Kami J. Maddocks;Amy S. Ruppert;Gerard Lozanski;Nyla A. Heerema

  • Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

    Gerard Lozanski;Nyla A. Heerema;Ian W. Flinn;Lisa Smith

  • Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

    Steven D. Gore;Stephen Baylin;Elizabeth Sugar;Hetty E. Carraway

  • Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

    William Blum;Ramiro Garzon;Rebecca B. Klisovic;Sebastian Schwind

  • Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997

    Ian W. Flinn;Donna S. Neuberg;Michael R. Grever;Gordon W. Dewald

  • A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

    James K. Weick;Kenneth J. Kopecky;Frederick R. Appelbaum;David R. Head

  • Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group

    Bruce D. Cheson;John M. Bennett;Kanti R. Rai;Michael R. Grever

  • RHODAMINE EFFLUX PATTERNS PREDICT P-GLYCOPROTEIN SUBSTRATES IN THE NATIONAL CANCER INSTITUTE DRUG SCREEN

    J S Lee;K Paull;M Alvarez;C Hose

  • A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

    John C. Byrd;Guido Marcucci;Mark R. Parthun;Jim J. Xiao

  • In vivo cultivation of tumor cells in hollow fibers.

    Melinda G. Hollingshead;Michael C. Alley;Richard F. Camalier;Betty J. Abbott

  • BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

    Jennifer A. Woyach;Amy S. Ruppert;Daphne Guinn;Amy Lehman

Frequent Co-Authors

John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Nyla A. Heerema
Nyla A. Heerema The Ohio State University
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Shujun Liu
Shujun Liu University of Minnesota
Steven M. Devine
Steven M. Devine The Ohio State University
A. Douglas Kinghorn
A. Douglas Kinghorn The Ohio State University
James T. Dalton
James T. Dalton St. Jude Children's Research Hospital
Michael A. Caligiuri
Michael A. Caligiuri City Of Hope National Medical Center
Kanti R. Rai
Kanti R. Rai Hofstra University
Donna Neuberg
Donna Neuberg Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several related online degrees and career pathways to explore. Many health professionals are choosing flexible education options to boost their credentials while balancing work and life commitments.

For those aiming at healthcare leadership roles, affordable mha online programs can provide you with management skills and industry knowledge at a competitive cost. Nurses looking to advance clinical practice may consider the best online dnp programs, which focus on evidence-based care and leadership.

Pharmacy professionals can now pursue an online pharmacy degree, making it possible to enhance credentials remotely. Additionally, the growth in healthcare data and technology has made a him degree online a popular choice for those interested in health information management.

Each pathway offers unique opportunities and the convenience of online learning, allowing you to tailor your education to your career goals in the rapidly evolving healthcare landscape.

Best Scientists Citing Michael R. Grever

Trending Scientists

Recently Published Articles